Welcome, this website is intended for all international healthcare professionals in uro-oncology. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): Final results of a multicenter phase II study

Plimack ER, Hoffman-Censits JH, Kutikov A, Greenberg RE, Bilusic M, Chen DYT, Viterbo R, Lallas CD, Lin J, Trabulsi EJ, Geynisman DM, Kelly WK, Smaldone MC, Devarajan K, Adaire-Halenda B, Cione C, Kilpatrick D, Duncan G, Wong YN.

Journal of Clinical Oncology (2014) 32:5 (Suppl; Abstract 4513)


Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre


URO ONCO is made possible by an unrestricted educational grant from:

The editorial independence of the resource centre is mandatory and recognized by the EAU and Elsevier.

The journal articles, videos and statements published on the resource centre have been selected independently and without influence from Elsevier, European Urology Editors or the sponsor and do not necessarily reflect their opinions or views.